8-K: Sigyn Secures $500K Note, Board Members Resign

Sigyn Therapeutics, Inc. entered into a convertible note purchase agreement for up to $550,000 while three directors resigned due to lapsed D&O insurance.

Summary

• Sigyn Therapeutics, Inc. (the Company) entered into a Convertible Note Purchase Agreement with Lambda Venture Partners, LLC on August 8, 2025.
• The agreement allows the Company to issue and sell up to $550,000 in aggregate principal amount of one-year 8% convertible promissory notes for $500,000.
• Notes are convertible into common stock at a 35% discount to the lowest traded price during the 10 trading days prior to conversion.
• The first tranche of notes, totaling $110,000 in principal, was issued on August 11, 2025, providing $100,000 in net proceeds to the Company after a $3,500 deduction for the buyer's legal fees.
• Proceeds from the notes are designated for general working capital.
• Three directors, Richa Nand, Michael Ryan, and Christopher Wetzel, resigned from the Board of Directors on August 8, 2025, and August 7, 2025, respectively.
• The resignations were prompted by the Company's directors and officers liability insurance policy expiring on August 4, 2025, without extension or replacement coverage.
• The Company is evaluating options for future D&O insurance coverage.

Sentiment

Score: 3

Explanation: The capital raise provides some liquidity, but the terms are highly dilutive and the simultaneous resignation of three directors due to lapsed D&O insurance signals severe corporate governance and risk management issues, outweighing the positive of securing funds.

Positives

• Secured up to $550,000 in potential funding through a convertible note, providing capital for general working capital.
• The initial tranche of $100,000 in net proceeds provides immediate liquidity.
• The Company maintains an engagement with a PCAOB registered accounting firm.

Negatives

• Three directors resigned due to the Company's discontinuation of directors and officers liability insurance coverage.
• The Company's D&O insurance expired on August 4, 2025, and replacement coverage has not yet been obtained, which could deter future board members or expose existing management to personal liability.
• The convertible notes are issued at an 8% interest rate and a 35% discount to the lowest traded price, indicating potentially dilutive terms for existing shareholders.
• The Company's obligation to repay the note within 60 days if it lacks sufficient authorized shares for conversion poses a financial risk.

Risks

• Dilution Risk: The convertible notes are convertible at a 35% discount to the lowest traded price, which could lead to significant dilution for existing shareholders upon conversion.
• Liquidity Risk: If the Company does not have enough authorized shares to satisfy conversion requests, it is obligated to repay the outstanding note amount in full within 60 days, potentially straining liquidity.
• Corporate Governance Risk: The lapse of Directors and Officers (D&O) liability insurance and subsequent resignations of three directors could make it difficult to attract and retain qualified board members, impacting governance and oversight.
• Operational Risk: Lack of D&O insurance may expose the Company and its management to increased personal liability, potentially affecting decision-making and risk-taking.
• Financial Reporting Risk: The Company's ability to maintain its fully reporting and current status under the Exchange Act is crucial for its trading market listing and investor confidence.

Future Outlook

The Company is evaluating alternatives for securing directors and officers liability insurance coverage in the future. It also intends to use the proceeds from the convertible notes for general working capital. The Company commits to maintaining its corporate existence and listing on the Trading Market, and to comply with Exchange Act reporting requirements.

Management Comments

• The resignations were based on the Company’s discontinuation of directors and officers liability insurance coverage.
• The Company is evaluating alternatives for securing such coverage in the future.
• The discontinuation of coverage was not related to any specific claim or proceeding against the Company or its directors or officers.

Industry Context

The lapse of D&O insurance and subsequent board resignations are significant red flags in the biotech/pharmaceutical industry, where litigation risk is often high. Securing capital through convertible notes with steep discounts and high interest rates is common for early-stage or distressed companies in this sector, reflecting challenges in attracting less dilutive financing. The use of proceeds for 'general working capital' suggests a need for operational funds rather than specific R&D milestones.

Comparison to Industry Standards

• The 35% discount on conversion price is a relatively high discount, often seen in highly speculative or distressed companies, indicating a significant cost of capital compared to more established biotech firms that might secure financing with lower discounts or traditional equity raises.
• The 8% interest rate on the convertible note is higher than typical corporate debt for stable companies but can be common for early-stage or high-risk ventures in the biotech sector.
• The lapse of D&O insurance is highly unusual and detrimental for a publicly traded company, especially in an industry prone to litigation. Most well-governed companies maintain robust D&O coverage to protect their board members and attract talent. This situation is a stark contrast to industry best practices.
• The resignation of three directors simultaneously due to D&O insurance lapse is a severe governance issue, unlike typical board rotations or individual departures seen in healthy companies.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Potential significant dilution from the convertible notes due to the 35% discount on conversion. The resignation of directors and lack of D&O insurance could erode investor confidence and negatively impact share price.
• Management/Directors: Increased personal liability risk due to the absence of D&O insurance.
• Creditors: The new convertible note adds to the Company's debt obligations. The clause requiring repayment if shares are insufficient for conversion could be a positive for the noteholder but a risk for the Company's overall financial health.

Next Steps

• Company to evaluate alternatives for securing directors and officers liability insurance coverage.
• Company to use proceeds from the notes for general working capital.
• Company to maintain its corporate existence and listing on the Trading Market.
• Company to comply with Exchange Act reporting requirements.
• Company to reserve 300% of shares for potential conversion of the notes.
• Company to offer participation rights and right of first refusal to Lambda Venture Partners, LLC for future capital raises.

Key Dates

Recommendation

The simultaneous resignation of three directors due to the lapse of D&O insurance is a severe corporate governance red flag, indicating significant underlying issues and increasing risk for all stakeholders. While the company secured a convertible note, the highly dilutive terms (35% discount) and high interest rate suggest financial distress and a high cost of capital. These factors collectively point to substantial operational and financial risks, making the stock a strong sell for seasoned investors.

Keywords

Convertible Note, SEC Filing, 8-K, Director Resignation, D&O Insurance, Capital Raise, Dilution, Corporate Governance, SIGYN THERAPEUTICS, Lambda Venture Partners